Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.

Zawertailo LA, Busto UE, Kaplan HL, Greenblatt DJ, Sellers EM.

J Clin Psychopharmacol. 2003 Jun;23(3):269-80.

PMID:
12826989
2.

The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo.

Gafni I, Busto UE, Tyndale RF, Kaplan HL, Sellers EM.

J Clin Psychopharmacol. 2003 Apr;23(2):169-75.

PMID:
12640218
3.

Treatment of codeine dependence with inhibitors of cytochrome P450 2D6.

Fernandes LC, Kilicarslan T, Kaplan HL, Tyndale RF, Sellers EM, Romach MK.

J Clin Psychopharmacol. 2002 Jun;22(3):326-9.

PMID:
12006904
4.

A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam.

Busto UE, Kaplan HL, Wright CE, Gomez-Mancilla B, Zawertailo L, Greenblatt DJ, Sellers EM.

J Clin Psychopharmacol. 2000 Dec;20(6):628-35.

PMID:
11106134
5.

Comparative abuse liability of intravenously administered remifentanil and fentanyl.

Baylon GJ, Kaplan HL, Somer G, Busto UE, Sellers EM.

J Clin Psychopharmacol. 2000 Dec;20(6):597-606.

PMID:
11106130
6.

Efficacy of dexfenfluramine in the treatment of alcohol dependence.

Romach MK, Sellers EM, Kaplan HL, Somer GR, Gomez-Mancilla B.

Alcohol Clin Exp Res. 2000 Oct;24(10):1534-41.

PMID:
11045862
7.

Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking.

Sellers EM, Kaplan HL, Tyndale RF.

Clin Pharmacol Ther. 2000 Jul;68(1):35-43.

PMID:
10945314
8.

Inhibition of cytochrome P450 2D6 modifies codeine abuse liability.

Kathiramalainathan K, Kaplan HL, Romach MK, Busto UE, Li NY, Säwe J, Tyndale RF, Sellers EM.

J Clin Psychopharmacol. 2000 Aug;20(4):435-44.

PMID:
10917405
9.

Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166)

Romach MK, Glue P, Kampman K, Kaplan HL, Somer GR, Poole S, Clarke L, Coffin V, Cornish J, O'Brien CP, Sellers EM.

Arch Gen Psychiatry. 1999 Dec;56(12):1101-6.

PMID:
10591286
10.

Identifying appropriate subjects for abuse liability studies using prestudy pharmacological testing.

Busto UE, Zawertailo LA, Kaplan HL, Sellers EM.

Can J Clin Pharmacol. 1999 Summer;6(2):103-10.

PMID:
10519736
11.

Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.

Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM.

J Clin Psychopharmacol. 1998 Aug;18(4):332-7.

PMID:
9690700
12.

A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation.

Romach MK, Kaplan HL, Busto UE, Somer G, Sellers EM.

J Clin Psychopharmacol. 1998 Apr;18(2):121-31.

PMID:
9555597
13.

Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability.

Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, Sellers EM.

J Pharmacol Exp Ther. 1997 Apr;281(1):103-8.

PMID:
9103485
14.

Clinical aspects of chronic use of alprazolam and lorazepam.

Romach M, Busto U, Somer G, Kaplan HL, Sellers E.

Am J Psychiatry. 1995 Aug;152(8):1161-7.

PMID:
7625464
15.

Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans.

Zawertailo LA, Busto U, Kaplan HL, Sellers EM.

J Clin Psychopharmacol. 1995 Apr;15(2):117-24. Erratum in: J Clin Psychopharmacol 1995 Jun;15(3):239.

PMID:
7782484
16.

Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans.

Busto U, Kaplan HL, Zawertailo L, Sellers EM.

Clin Pharmacol Ther. 1994 Apr;55(4):451-63.

PMID:
8162672
17.

CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.

Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM.

Clin Pharmacol Ther. 1993 Nov;54(5):463-72.

PMID:
7693389
18.

Characteristics of long-term alprazolam users in the community.

Romach MK, Somer GR, Sobell LC, Sobell MB, Kaplan HL, Sellers EM.

J Clin Psychopharmacol. 1992 Oct;12(5):316-21.

PMID:
1479048
19.

Comparative drug effects and abuse liability of lorazepam, buspirone, and secobarbital in nondependent subjects.

Sellers EM, Schneiderman JF, Romach MK, Kaplan HL, Somer GR.

J Clin Psychopharmacol. 1992 Apr;12(2):79-85.

PMID:
1573044
20.

Abuse liability of bretazenil and other partial agonists.

Sellers EM, Kaplan HL, Busto UE.

Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:409A. No abstract available.

PMID:
1354047
21.

Kinetic and dynamic interactions of oral viqualine and ethanol in man.

Sullivan JT, Naranjo CA, Shaw CA, Kaplan HL, Kadlec KE, Sellers EM.

Eur J Clin Pharmacol. 1989;36(1):93-6.

PMID:
2917597
22.

Pharmacokinetic and pharmacodynamic drug interactions: implications for abuse liability testing.

Sellers EM, Busto U, Kaplan HL.

NIDA Res Monogr. 1989;92:287-306. Review. No abstract available.

PMID:
2512498
23.

Limitations in the measurement of urine ethanol in clinical trials to monitor ethanol consumption.

Sellers EM, Kadlec KE, Kaplan HL, Naranjo CA.

J Stud Alcohol. 1988 Nov;49(6):567-70.

PMID:
2976866
24.

Comparative neurologic effects of diazepam and suriclone, a cyclopyrrolone anxiolytic.

Shaw CA, Sellers EM, Sullivan JT, Kaplan HL.

J Clin Psychopharmacol. 1988 Jun;8(3):189-92.

PMID:
2897978
25.

Effects of hydrogen chloride on respiratory response and pulmonary function of the baboon.

Kaplan HL, Anzueto A, Switzer WG, Hinderer RK.

J Toxicol Environ Health. 1988;23(4):473-93.

PMID:
3129573
26.
27.

Detection theory analysis of group data: estimating sensitivity from average hit and false-alarm rates.

Macmillan NA, Kaplan HL.

Psychol Bull. 1985 Jul;98(1):185-99. No abstract available.

PMID:
4034817
28.

Is there acute tolerance to alcohol at steady state?

Kaplan HL, Sellers EM, Hamilton C, Naranjo CA, Dorian P.

J Stud Alcohol. 1985 May;46(3):253-6.

PMID:
4010303
29.

Triazolam and ethanol interaction: kinetic and dynamic consequences.

Dorian P, Sellers EM, Kaplan HL, Hamilton C, Greenblatt DJ, Abernethy D.

Clin Pharmacol Ther. 1985 May;37(5):558-62.

PMID:
2859136
30.

Pharmacokinetic interaction of propoxyphene with ethanol.

Sellers EM, Hamilton CA, Kaplan HL, Degani NC, Foltz RL.

Br J Clin Pharmacol. 1985 Mar;19(3):398-401.

31.

Acute kinetic and dynamic interactions of zimelidine with ethanol.

Naranjo CA, Sellers EM, Kaplan HL, Hamilton C, Khouw V.

Clin Pharmacol Ther. 1984 Nov;36(5):654-60.

PMID:
6237836
32.

Diazepam tapering in detoxification for high-dose benzodiazepine abuse.

Harrison M, Busto U, Naranjo CA, Kaplan HL, Sellers EM.

Clin Pharmacol Ther. 1984 Oct;36(4):527-33.

PMID:
6434221
33.

Ethanol-induced inhibition of hepatic uptake of propranolol in perfused rat liver and in man.

Dorian P, Sellers EM, Kaplan HL, Carruthers G, Hamilton C, Khouw V.

Eur J Clin Pharmacol. 1984;27(2):209-15.

PMID:
6499899
34.

A long-term inhalation study evaluates the pulmonary effects of diesel emissions.

White H, Vostal JJ, Kaplan HL, MacKenzie WF.

J Appl Toxicol. 1983 Dec;3(6):332. No abstract available.

PMID:
6203955
35.

Amitriptyline and ethanol: pharmacokinetic and pharmacodynamic interaction.

Dorian P, Sellers EM, Reed KL, Warsh JJ, Hamilton C, Kaplan HL, Fan T.

Eur J Clin Pharmacol. 1983;25(3):325-31.

PMID:
6628520
36.

A subchronic study of the effects of exposure of three species of rodents to diesel exhaust.

Kaplan HL, MacKenzie WF, Springer KJ, Schreck RM, Vostal JJ.

Dev Toxicol Environ Sci. 1982;10:161-82. No abstract available.

PMID:
6176421
37.

Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care.

Shaw JM, Kolesar GS, Sellers EM, Kaplan HL, Sandor P.

J Clin Psychopharmacol. 1981 Nov;1(6):382-89.

PMID:
7334148
38.

Age- and sex-related differences in patterns of drug overdose and abuse.

Busto U, Kaplan HL, Sellers EM.

Soc Sci Med E. 1981 Nov;15(4):275-82. No abstract available.

PMID:
7323849
39.
40.

Acute and chronic drug abuse emergencies in Metropolitan Toronto.

Sellers EM, Marshman JA, Kaplan HL, Giles HG, Kapur BM, Busto U, MacLeod SM, Stapleton C, Sealey F.

Int J Addict. 1981 Feb;16(2):283-303.

PMID:
7275381
41.

Alcohol use by patients admitted to hospital emergency rooms for treatment of drug overdose and misuse.

Kaplan HL, Sellers EM, Marshman JA, Giles HG, MacLeod SM, Kapur BM, Stapleton C, Sealey F, Busto U.

J Stud Alcohol. 1980 Sep;41(9):882-93.

PMID:
7206719
42.

EEG correlates of the alcohol-induced organic brain syndrome in man.

Zilm DH, Huszar L, Carlen PL, Kaplan HL, Wilkinson DA.

Clin Toxicol. 1980 May;16(3):345-58.

PMID:
7398222
43.

Benzodiazepine-associated emergencies in Toronto.

Busto U, Kaplan HL, Sellers EM.

Am J Psychiatry. 1980 Feb;137(2):224-7.

PMID:
6101526
44.

Effect of adverse drug reactions on the length of hospitalization.

Spino M, Sellers EM, Kaplan HL.

Am J Hosp Pharm. 1978 Sep;35(9):1060-4. No abstract available.

PMID:
696748
45.

Adverse biochemical and clinical consequences of furosemide administration.

Spino M, Sellers EM, Kaplan HL, Stapleton C, MacLeod SM.

Can Med Assoc J. 1978 Jun 24;118(12):1513-8.

46.

Effects of ketones on lever-pressing behavior of rats.

Garcia CR, Geller I, Kaplan HL.

Proc West Pharmacol Soc. 1978;21:433-8. No abstract available.

PMID:
693530
47.

Effects of carbon monoxide on two behavioral measures in the rat.

Russo DM, Kaplan HL.

Proc West Pharmacol Soc. 1978;21:419-25. No abstract available.

PMID:
693528
48.

Effects of ketones on a match to sample task in the baboon.

Geller I, Martinez RL, Hartmann RJ, Kaplan HL.

Proc West Pharmacol Soc. 1978;21:439-42. No abstract available.

PMID:
99750
49.

The psychophysics of categorical perception.

Macmillan NA, Kaplan HL, Creelman CD.

Psychol Rev. 1977 Sep;84(5):452-71. No abstract available.

PMID:
905471
50.

The five distractors experiment: exploring the critical band with contaminated white noise.

Kaplan HL.

J Acoust Soc Am. 1975 Aug;58(2):404-11. No abstract available.

PMID:
1184834

Supplemental Content

Loading ...
Support Center